CAS 96445-14-6

(5alfa)-17-(ciclopropilmetil)-3,14-diidroxi-4,5-epoximorfinano-6,10-diona

Fórmula: C₂₀H₂₁NO₅

InChI: InChI=1/C20H21NO5/c22-12-4-3-11-14-16(12)26-18-13(23)5-6-20(25)17(15(11)24)21(9-10-1-2-10)8-7-19(14,18)20/h3-4,10,17-18,22,25H,1-2,5-9H2/t17-,18+,19+,20-/m1/s1

Chave InChI: MLHMRULRADVYER-FUMNGEBKSA-N

SMILES: C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2C(=O)C6=C4C(=C(C=C6)O)O5)O

Sinónimos:

• Naltrexone EP Impurity I

10-Oxo Naltrexone

Produto Controlado

CAS: 96445-14-6

Impurity Naltrexone EP Impurity I
Applications Naltrexone derivative. It is less potent than Naltrexone (N285750) and Oxymorphone (O876800).
References Archer, S., et al.: J. Med. Chem., 28 974 (1985),

Fórmula: C₂₀H₂₁NO₅

Cor e Forma: Neat

Peso molecular: 355.38

Ref: TR-O858200

10-Oxo Naltrexone (1 mg/ml in Acetonitrile)

Produto Controlado

CAS: 96445-14-6

Fórmula: C₂₀H₂₁NO₅

Cor e Forma: Single Solution

Peso molecular: 355.38

Ref: TR-KIT6765

10-Ketonaltrexone - in methanol solution

Produto Controlado

CAS: 96445-14-6

10-Ketonaltrexone is an opioid receptor antagonist that binds to the μ- and δ-opioid receptors in the gastrointestinal tract, blocking the effect of opioids. It has been shown to selectively inhibit binding of oxycodone, cyclazocine, and morphine to their receptors in muscle and deferens tissue. 10-Ketonaltrexone has affinity for opioid receptors in ileum tissue and binding sites in the brain. This drug is selective for the μ-receptors over δ-receptors and has no activity against other receptors such as dopamine, serotonin, or histamine. In vitro assays have shown that 10-ketonaltrexone binds with high affinity to human naltrexone binding sites but not to human oxymorphone binding sites.

Fórmula: C₂₀H₂₁NO₅

Pureza: Min. 95%

Peso molecular: 355.38 g/mol

Ref: 3D-FK71982

Naltrexone EP Impurity I

CAS: 96445-14-6

Fórmula: C₂₀H₂₁NO₅

Peso molecular: 355.4

Ref: ST-EA-CP-N57008

Naltrexone impurity I

Produto Controlado

CAS: 96445-14-6

Naltrexone impurity I is an impurity of naltrexone that can be found in the drug oxymorphone. It is a selective opiate antagonist that binds to opiate receptors in the brain, including those in the myenteric plexus and ileum. The affinity of naltrexone for these binding sites is much lower than that of oxycodone or oxymorphone. This means it will not displace these drugs from their binding sites and will therefore not cause withdrawal symptoms when used as a substitute for these drugs. Naltrexone impurity I also has low affinity for muscle tissue, which makes it suitable for use as a long-acting injectable drug.

Fórmula: C₂₀H₂₁NO₅

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 355.38 g/mol

Ref: 3D-IN167109